TX-FLUENCE
14.7.2022 15:02:08 CEST | Business Wire | Press release
Fluence , a leading global provider of energy-efficient LED lighting solutions for commercial cannabis and food production, announced today its exclusive partnership with BioLumic , a plant-growth biotechnology company that harnesses the power of ultraviolet (UV) light to sustainably increase plant yields, health and quality with Light Signal Recipes™. Under the agreement, Fluence and BioLumic will collaborate to deliver BioLumic’s cutting-edge UV Light Signals through Fluence’s industry-leading LED lighting solutions.
BioLumic’s patented technology leverages UV photomorphogenesis to trigger biological events in seeds and young plants to dramatically optimize plant performance. The company’s proven UV Light Signal Recipes™ can induce large gains in plant yields, desirable plant traits and vigor while also activating natural plant resistance to disease and pests.
“Our goal at Fluence is to drive cutting-edge plant science and innovations in agriculture technology,” said David Cohen, CEO of Fluence. “We’re excited to pursue that goal in collaboration with BioLumic and create the next generation of leading lighting solutions for cannabis and produce growers around the world.”
Fluence’s lighting systems will deliver BioLumic’s dynamic UV light treatments in the propagation phase of plant production—one-time treatments that trigger benefits that accrue through the entire plant growth cycle. Pairing BioLumic and Fluence’s leading market solutions enables cultivators to achieve high-quality yield gains, enhance cannabinoid levels and improve overall plant quality while reducing cycle-to-cycle variability.
“BioLumic’s Light Signal Recipes™ allow cultivators to fully and frictionlessly harness UV lighting to improve plant growth and genetic expression without big input costs or chemicals,” said Steve Sibulkin, CEO of BioLumic. “This partnership will accelerate the development of BioLumic’s Light Signal Platform, increase our company’s access to the global horticulture market and strengthen Fluence’s horticultural lighting portfolio. It’s a tremendous win for growers looking for new ways to grow more with less.”
The partnership reinforces Fluence’s deep history of science-led innovation in photobiology and follows several product launches this year, including RAPTR, RAZR Modular System, VYNE, SPYDR Fang, SPYDR 2h and Wireless Flex Dimming. Fluence’s dynamic and expanding suite of luminaires and lighting controls empowers growers with advanced lighting technology that meets and exceeds cultivation goals.
Fluence and BioLumic will initially work with select cannabis cultivation partners while industrializing commercial delivery systems for UV light that enhance Fluence’s end-to-end product offering in 2023. For more information about BioLumic, please visit www.biolumic.com . For more information about Fluence, visit www.fluence.science .
About Fluence
Fluence Bioengineering, Inc. (Fluence) creates powerful and energy-efficient LED lighting solutions for commercial crop production and research applications. Fluence is a leading LED lighting supplier in the global cannabis market and is committed to enabling more efficient crop production with the world’s top vertical farms and greenhouse produce growers. Fluence global headquarters are in Austin, Texas, with its EMEA headquarters in Rotterdam, Netherlands. Fluence operates as a business unit within Signify’s Digital Solutions division. For more information about Fluence, visit www.fluence.science .
About BioLumic
BioLumic is an agricultural biotech company that programs plants with light to unlock growth, quality and disease-resistance. The company's Light Signal Recipe™ platform combines biological insights and genetic marker knowledge to mediate genetic expression with a one-time application of light signals. These treatments are scalable and require no chemical application, genetic modification, facility expansion or large input costs. BioLumic has worked with 12 crops, including cannabis, soybeans, corn, leafy greens and strawberries. In cannabis, the company has helped cultivators produce large double-digit gains in dry flower yield, THC concentration, minor cannabinoids and terpene expression. To learn more, visit www.biolumic.com or send an email to info@biolumic.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20220714005019/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Integrated Hubs for Green Chemistry Research Aim to Transform How Chemicals and Materials Are Designed12.11.2026 17:00:00 CET | Press release
International network will investigate fundamental principles for creating safer, higher-performing chemicals and materials The Gordon and Betty Moore Foundation today announced four Integrated Research Hubs to explore new frontiers in chemical design, from materials that respond to their surroundings to molecules designed for safety from the start. Bringing together global researchers across institutions and disciplines, the hubs will investigate fundamental principles that could enable new capabilities in chemicals and materials while improving performance and protecting human health and the environment. The research priorities emerged through extensive engagement with the scientific community to identify the questions that could transform what chemistry can achieve. Each hub will connect researchers across institutions around one of four green chemistry focus areas: Safer molecular design: Led by The George Washington University, this hub will combine artificial intelligence and qua
Roquette Highlights Scalable Excipient and Capsule Solutions for Regional and Global Pharmaceutical Markets at CPHI India 202612.11.2026 16:00:00 CET | Press release
Helping pharmaceutical manufacturers accelerate the journey from formulation to market through deep technical expertise, meaningful innovation, close collaboration and global capabilities Roquette, a global leader in plant-based ingredients and a leading provider of pharmaceutical excipients, will showcase its comprehensive portfolio of excipient and capsule solutions at CPHI India 2026, Hall 1, Booth 1I12 from November 23 to 25, 2026. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261112803410/en/ Meet Roquette at CPHI India 2026, Hall 1, Booth 1I12 At the event, Roquette will demonstrate how it helps pharmaceutical manufacturers accelerate the journey from formulation to market with confidence. By combining technical expertise, trusted quality, meaningful innovation and close collaboration, Roquette helps customers address formulation, scale-up and manufacturing challenges across a broad range of pharmaceutical application
Tigo Energy and Google Cloud Pair AI-Powered Tools for Solar Installers and Utilities12.11.2026 15:00:00 CET | Press release
The collaboration combines Tigo software with Google’s Gemini models on Google Cloud to help automate installer and utility operations for distributed energy portfolios. Tigo Energy, Inc. (NASDAQ: TYGO) (“Tigo” or “Company”), a leading provider of intelligent solar and energy software solutions, today announced a collaboration with Google Cloud to develop AI-enabled operational workflows for solar installers and distributed energy portfolios. By making core Tigo data and software products available through Google Cloud, Tigo aims to deliver faster deployment, simplified data integration, and additional insights with Gemini. The resulting workflows will help installers, asset managers, and energy operators more easily identify issues, prioritize actions, and automate routine operational tasks across growing fleets of distributed energy systems. As solar and storage portfolios expand, energy businesses are increasingly responsible for managing more sites, more system data, and more custo
Patsnap Releases State of Pharma Intelligence 2026 Report, Reveals Pharma's Cautious Embrace of AI in Decision-Making12.11.2026 15:00:00 CET | Press release
A new survey of 130 senior life sciences leaders on AI in pharma R&D and competitive intelligence finds that 92% can name a recent R&D, portfolio, or partnership decision where AI changed the outcome. Patsnap, the AI-native innovation intelligence company for IP and R&D teams, today released "State of Pharma Intelligence 2026: The Confidence to Act", a benchmark report on how pharma teams use and trust AI in R&D, competitive intelligence and business development decisions. The report draws on responses from 130 senior leaders at Director level or above across the United States, the United Kingdom, Germany, Switzerland, and France, spanning drug developers, CDMOs/CMOs, CROs, and consulting and professional services firms. The survey was fielded in August 2026 in partnership with NewtonX. Patsnap commissioned the research to understand how AI is influencing decisions across pharma R&D and business development, what builds confidence in its output, and where intelligence workflows fall sh
REPLY: the Board of Directors Approves the Quarterly Financial Report as of 30 September 202612.11.2026 14:41:00 CET | Press release
All economic indicators have substantially improved:Consolidated turnover of €1,987.9 million (1,819.8 as at 30 September 2025)EBITDA of €354.9 million (335.5 as at 30 September 2025)EBIT of €286.7 million (281.0 as at 30 September 2025)Pre-tax profit of €291.6 million (268.1 as at 30 September 2025)Positive Net Financial Position of €397.0 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2026. The Group's consolidated turnover in the first nine months of the year reached €1,987.9 million, an increase of 9.2% compared to €1,819.8 million recorded on 30 September 2025. The indicators for the period are positive. Consolidated EBITDA was €354.9 million, equal to 17.9% of the consolidated revenues. As of September 2025 EBITDA was €335.5 million. EBIT, from January to September, reached €286.7 million, equal to 14.4% of the consolidated revenues. The corresponding 2025 figure was €281.0 million. Pre-tax profit, from January to Septembe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom